CDNA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CareDx Inc (CDNA) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 to invest. The stock has strong positive catalysts, including a recent divestment deal, robust revenue growth in its Testing Service segment, and a bullish technical setup. Despite some financial weaknesses, the stock is undervalued according to analysts, and the long-term growth potential outweighs short-term concerns.
The stock is in a strong bullish trend with MACD above 0 and expanding positively, RSI at 83.928 indicating overbought conditions, and bullish moving averages (SMA_5 > SMA_20 > SMA_200). Key resistance levels are at R1: 21.523 and R2: 23.234, while support levels are at S1: 15.984 and S2: 14.273.
CareDx announced the divestment of its Lab Products business to EuroBio Scientific for $170 million in cash, boosting investor confidence.
Strong Q1 revenue guidance of approximately $118 million, with Testing Service revenue expected to grow by 48%.
Analysts raised price targets, citing undervaluation and strong revenue guidance.
Financial performance shows a decline in net income (-105.27% YoY) and EPS (-107.14% YoY).
Gross margin slightly dropped to 67.24%.
Overbought RSI indicates potential short-term pullback risk.
In Q4 2025, revenue increased by 25.19% YoY to $108.39 million, indicating strong top-line growth. However, net income dropped significantly to -$4.11 million, and EPS declined to -$0.08, reflecting profitability challenges.
BTIG raised the price target from $25 to $26, maintaining a Buy rating. Analysts believe the stock is undervalued and has strong growth potential despite uncertainties related to CMS resolution.
